热景生物两个月获超百家机构密集调研 创新药与AI布局成关注焦点

Core Insights - The company, 热景生物, has garnered significant attention from over 100 institutional investors during February and March 2023, indicating strong market interest in its long-term value [1] - The company has set ambitious revenue growth targets for 2024 to 2026, aiming for a minimum growth rate of 20%, 44%, and 73% respectively, with projected revenues of 490 million, 588 million, and 707 million yuan [2] - 热景生物 is accelerating its international expansion strategy, establishing subsidiaries in the US, India, and Hong Kong, and has obtained over 600 international certifications to enhance its global market presence [3] - The company has made breakthroughs in its innovative drug pipeline, including a first-in-class emergency drug for acute myocardial infarction and a monoclonal antibody for Alzheimer's disease, both of which have received clinical trial approvals [4] - The company is integrating AI technology into its medical diagnostics, with the launch of the X-Gen AI drug development center, which aims to improve early liver cancer diagnosis and enhance research efficiency through collaborations [5]